academic article

• von Drygalski, A., Bhat, V., Gale, A. J., Averell, P. M., Cramer, T. J., Elias, D. J., Griffin, J. H., Mosnier, L. O. An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms Blood Advances  2020 4:3716-3727  DOI:10.1182/bloodadvances.2020001699  PMID:32777068  PMCID:PMC7422119
• Mosnier, L. O. How much clotting is enough? Blood  2020 136:651-652  DOI:10.1182/blood.2020006443  PMID:32761220  PMCID:PMC7414588
• Heeb, M. J., Fernandez, J. A., Yamashita, A., McDowell, O. R., Guo, Z. H., Mosnier, L. O., Deguchi, H., Griffin, J. H. Activated protein C anticoagulant activity is enhanced by skeletal muscle myosin Haematologica  2020 105:E424-E427  DOI:10.3324/haematol.2019.242982  PMID:31857364  PMCID:PMC7395292
• Zhao, X. Y., Wilmen, A., Wang, D. L., Wang, X. Q., Bauzon, M., Kim, J. Y., Linden, L., Li, L., Egner, U., Marquardt, T., Moosmayer, D., Tebbe, J., et al. Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia Nature Communications  2020 11  DOI:10.1038/s41467-020-16720-9  PMID:32532974  PMCID:PMC7293249
• Yamashita, A., Zhang, Y. Q., Sanner, M. F., Griffin, J. H., Mosnier, L. O. C-terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities Journal of Thrombosis and Haemostasis  2020 18:1027-1038  DOI:10.1111/jth.14756  PMID:32017367
• Zilberman-Rudenko, J., Deguchi, H., Shukla, M., Oyama, Y., Orje, J. N., Guo, Z. H., Wyseure, T., Mosnier, L. O., McCarty, O. J. T., Ruggeri, Z. M., Eckle, T., Griffin, J. H. Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo Arteriosclerosis Thrombosis and Vascular Biology  2020 40:901-913  DOI:10.1161/atvbaha.120.313990  PMID:32102568  PMCID:PMC7135739
• Basu, S., Liang, H. P. H., Hernandez, I., Zogg, M., Fields, B., May, J., Ogoti, Y., Wyseure, T., Mosnier, L. O., Burns, R. T., Carlson, K., Weiler, H. Role of thrombomodulin expression on hematopoietic stem cells Journal of Thrombosis and Haemostasis  2020  DOI:10.1111/jth.14663  PMID:31628891
• Cooke, E. J., Wyseure, T., Zhou, J. Y., Gopal, S., Nasamran, C. A., Fisch, K. M., Manon-Jensen, T., Karsdal, M. A., Mosnier, L. O., von Drygalski, A. Mechanisms of vascular permeability and remodeling associated with hemarthrosis in factor VIII-deficient mice Journal of Thrombosis and Haemostasis  2019  DOI:10.1111/jth.14567  PMID:31301687
• Wyseure, T., Yang, T., Zhou, J. Y., Cooke, E. J., Wanko, B., Olmer, M., Agashe, R., Morodomi, Y., Behrendt, N., Lotz, M., Morser, J., von Drygalski, A., et al. TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding JCI Insight  2019 4  DOI:10.1172/jci.insight.128379  PMID:31465300
• Mosnier, L. O. Activated protein C in neuroprotection and malaria Current Opinion in Hematology  2019 26:320-330  DOI:10.1097/moh.0000000000000528  PMID:31348046
• Lopez-Ramirez, M. A., Pham, A., Girard, R., Wyseure, T., Hale, P., Yamashita, A., Koskimaki, J., Polster, S., Saadat, L., Romero, I. A., Esmon, C. T., Lagarrigue, F., et al. Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice Blood  2019 133:193-204  DOI:10.1182/blood-2018-06-856062  PMID:30442679  PMCID:PMC6337879
• Adams, G. N., Sharma, B. K., Rosenfeldt, L., Frederick, M., Flick, M. J., Witte, D. P., Mosnier, L. O., Harmel-Laws, E., Steinbrecher, K. A., Palumbo, J. S. Protease-activated receptor-1 impedes prostate and intestinal tumor progression in mice Journal of Thrombosis and Haemostasis  2018 16:2258-2269  DOI:10.1111/jth.14277  PMID:30152921  PMCID:PMC6214773
• Wyseure, T., Cooke, E. J., Declerck, P. J., Behrendt, N., Meijers, J. C. M., von Drygalski, A., Mosnier, L. O. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding Blood  2018 132:1593-1603  DOI:10.1182/blood-2018-01-828434  PMID:30026184  PMCID:PMC6182268
• Griffin, J. H., Zlokovic, B. V., Mosnier, L. O. Activated protein C, protease activated receptor 1, and neuroprotection Blood  2018 132:159-169  DOI:10.1182/blood-2018-02-769026  PMID:29866816  PMCID:PMC6043978
• Mosnier, L. O. Warfarin, a juggler's demise Blood  2018 131:2742-2743  DOI:10.1182/blood-2018-05-843151  PMID:29930151  PMCID:PMC6014355
• Cooke, E. J., Zhou, J. Y., Wyseure, T., Joshi, S., Bhat, V., Durden, D. L., Mosnier, L. O., von Drygalski, A. Vascular permeability and remodelling coincide with inflammatory and reparative processes after joint bleeding in factor VIII-deficient mice Thrombosis and Haemostasis  2018 118:1036-1047  DOI:10.1055/s-0038-1641755  PMID:29847841
• Sinha, R. K., Wang, Y., Zhao, Z., Xu, X., Burnier, L., Gupta, N., Fernandez, J. A., Martin, G., Kupriyanov, S., Mosnier, L. O., Zlokovic, B. V., Griffin, J. H. PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke Blood  2018 131:1163-1171  DOI:10.1182/blood-2017-10-810895  PMID:29343482  PMCID:PMC5855020
• Spronk, H. M. H., Padro, T., Siland, J. E., Prochaska, J. H., Winters, J., van der Wal, A. C., Posthuma, J. J., Lowe, G., d'Alessandro, E., Wenzel, P., Coenen, D. M., Reitsma, P. H., et al. Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis Thrombosis and Haemostasis  2018 118:229-250  DOI:10.1160/th17-07-0492  PMID:29378352
• Fernandez, J. A., Xu, X., Sinha, R. K., Mosnier, L. O., Sanner, M. F., Griffin, J. H. Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S Blood Advances  2017 1:1423-1426  DOI:10.1182/bloodadvances.2017007005  PMID:29296783  PMCID:PMC5727852
• Griffin, J. H., Mosnier, L. O., Fernandez, J. A., Zlokovic, B. V. 2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis. Thrombotic stroke: neuroprotective therapy by recombinant-activated protein C Arteriosclerosis Thrombosis and Vascular Biology  2016 36:2143-2151  DOI:10.1161/atvbaha.116.308038  PMID:27758767  PMCID:PMC5119536
• Gale, A. J., Bhat, V., Pellequer, J. L., Griffin, J. H., Mosnier, L. O., Von Drygalski, A. Safety, stability and pharmacokinetic properties of (super)Factor Va, a novel engineered coagulation Factor V for treatment of severe bleeding Pharmaceutical Research  2016 33:1517-1526  DOI:10.1007/s11095-016-1895-3  PMID:26960296  PMCID:PMC4854778
• Mosnier, L. O., Lavstsen, T. The role of EPCR in the pathogenesis of severe malaria Thrombosis Research  2016 141:S46-S49  PMID:27207424
• Sinha, R. K., Yang, X. V., Fernandez, J. A., Xu, X., Mosnier, L. O., Griffin, J. H. Apolipoprotein E receptor 2 mediates activated protein C-induced endothelial Akt activation and endothelial barrier stabilization Arteriosclerosis Thrombosis and Vascular Biology  2016 36:518-524  DOI:10.1161/atvbaha.115.306795  PMID:26800564  PMCID:PMC4816599
• Cramer, T. J., Anderson, K., Navaz, K., Brown, J. M., Mosnier, L. O., von Drygalski, A. Heterozygous congenital Factor VII deficiency with the 9729de14 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male Blood Cells Molecules and Diseases  2016 57:8-12  DOI:10.1016/j.bcmd.2015.11.004  PMID:26852649  PMCID:PMC4874642
• Bhat, V., von Drygalski, A., Gale, A. J., Griffin, J. H., Mosnier, L. O. Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa Thrombosis and Haemostasis  2016 115:551-561  DOI:10.1160/th15-07-0525  PMID:26466980  PMCID:PMC4775351
• Wyseure, T., Mosnier, L. O., von Drygalski, A. Advances and challenges in hemophilic arthropathy Seminars in Hematology  2016 53:10-19  DOI:10.1053/j.seminhematol.2015.10.005  PMID:26805902  PMCID:PMC5034876
• Bouwens, E. A. M., Stavenuiter, F., Mosnier, L. O. Cell painting with an engineered EPCR to augment the protein C system Thrombosis and Haemostasis  2015 114:1144-1155  DOI:10.1160/th15-01-0079  PMID:26272345
• Petersen, J. E. V., Bouwens, E. A. M., Tamayo, I., Turner, L., Wang, C. W., Stins, M., Theander, T. G., Hermida, J., Mosnier, L. O., Lavstsen, T. Protein C system defects inflicted by the malaria parasite protein PfEMP1 can be overcome by a soluble EPCR variant Thrombosis and Haemostasis  2015 114:1038-1048  DOI:10.1160/th15-01-0018  PMID:26155776
• Bhat, V., Olmer, M., Joshi, S., Durden, D. L., Cramer, T. J., Barnes, R. F. W., Ball, S. T., Hughes, T. H., Silva, M., Luck, J. V., Moore, R. E., Mosnier, L. O., et al. Vascular remodeling underlies rebleeding in hemophilic arthropathy American Journal of Hematology  2015 90:1027-1035  DOI:10.1002/ajh.24133  PMID:26257191  PMCID:PMC4618067
• Griffin, J. H., Zlokovic, B. V., Mosnier, L. O. Activated protein C: biased for translation Blood  2015 125:2898-2907  DOI:10.1182/blood-2015-02-355974  PMID:25824691  PMCID:PMC4424414
• Stavenuiter, F., Mosnier, L. O. Noncanonical PAR3 activation by factor Xa identifies a novel pathway for Tie2 activation and stabilization of vascular integrity Blood  2014 124:3480-3489  DOI:10.1182/blood-2014-06-582775  PMID:25320242  PMCID:PMC4246042
• Mosnier, L. O., Zlokovic, B. V., Griffin, J. H. Cytoprotective-selective activated protein C therapy for ischaemic stroke Thrombosis and Haemostasis  2014 112:883-892  DOI:10.1160/th14-05-0448  PMID:25230930
• von Drygalski, A., Bhat, V., Gale, A. J., Burnier, L., Cramer, T. J., Griffin, J. H., Mosnier, L. O. An engineered Factor Va prevents bleeding induced by anticoagulant wt activated protein C PLoS One  2014 9:e104304  DOI:10.1371/journal.pone.0104304  PMID:25127130  PMCID:PMC4134195
• von Drygalski, A., Cramer, T. J., Bhat, V., Griffin, J. H., Gale, A. J., Mosnier, L. O. Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant Journal of Thrombosis and Haemostasis  2014 12:363-372  DOI:10.1111/jth.12489  PMID:24818532  PMCID:PMC4161283
• Mosnier, L. O. PolyP and APC fight a RAGEing battle Blood  2014 123:804-806  DOI:10.1182/blood-2013-12-541243  PMID:24505066  PMCID:PMC3916875
• Aird, W. C., Mosnier, L. O., Fairhurst, R. M. Plasmodium falciparum picks (on) EPCR Blood  2014 123:163-167  DOI:10.1182/blood-2013-09-521005  PMID:24246501  PMCID:PMC3888284
• Mosnier, L. O., Fernandez, J. A., Davis, T. P., Zlokovic, B. V., Griffin, J. H. Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity Journal of Thrombosis and Haemostasis  2013 11:2059-2062  DOI:10.1111/jth.12400  PMID:24034518  PMCID:PMC3850769
• Wang, Y., Sinha, R. K., Mosnier, L. O., Griffin, J. H., Zlokovic, B. V. Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice Blood Cells Molecules and Diseases  2013 51:104-108  DOI:10.1016/j.bcmd2013.02.009  PMID:23541526
• Burnier, L., Mosnier, L. O. Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3 Blood  2013 122:807-816  DOI:10.1182/blood-2013-03-488957  PMID:23788139  PMCID:PMC3731934
• von Drygalski, A., Kolaitis, N. A., Bettencourt, R., Bergstrom, J., Kruse-Jarres, R., Quon, D. V., Wassel, C., Li, M. C., Waalen, J., Elias, D. J., Mosnier, L. O., Allison, M. Prevalence and risk factors for hypertension in hemophilia Hypertension  2013 62:209-215  DOI:10.1161/hypertensionaha.113.01174  PMID:23630949
• Bouwens, E. A. M., Stavenuiter, F., Mosnier, L. O. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway Journal of Thrombosis and Haemostasis  2013 11:242-253  DOI:10.1111/jth.12247  PMID:23809128  PMCID:PMC3713536
• von Drygalski, A., Furlan-Freguia, C., Ruf, W., Griffin, J. H., Mosnier, L. O. Organ-specific protection against lipopolysaccharide-induced vascular leak is dependent on the endothelial protein C receptor Arteriosclerosis, Thrombosis, and Vascular Biology  2013 33:769-776  DOI:10.1161/atvbaha.112.301082  PMID:23393392
• Stavenuiter, F., Bouwens, E. A., Mosnier, L. O. Down-regulation of the clotting cascade by the protein C pathway Hematology Education  2013 7:365-374  PMID:24741378  PMCID:PMC3985519
• Mosnier, L. O., Sinha, R. K., Burnier, L., Bouwens, E. A., Griffin, J. H. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46 Blood  2012 120:5237-5246  DOI:10.1182/blood-2012-08-452169  PMID:23149848  PMCID:PMC3537315
• von Drygalski, A., Furlan-Freguia, C., Mosnier, L. O., Yegneswaran, S., Ruf, W., Griffin, J. H. Infrared fluorescence for vascular barrier breach in vivo - a novel method for quantitation of albumin efflux Thrombosis and Haemostasis  2012 108:981-991  DOI:10.1160/th12-03-0196  PMID:23052565  PMCID:PMC3597782
• Griffin, J. H., Zlokovic, B. V., Mosnier, L. O. Protein c anticoagulant and cytoprotective pathways International Journal of Hematology  2012 95:333-345  DOI:10.1007/s12185-012-1059-0  PMID:22477541  PMCID:PMC3413316
• Bouwens, E. A., Mosnier, L. O. EPCR encryption induces cellular APC resistance Blood  2012 119:2703-2705  DOI:10.1182/blood-2012-01-400762  PMID:22442333
• Mosnier, L. O. A knockout for knockin Blood  2011 117:6058-6060  DOI:10.1182/blood-2011-04-345553
• Mosnier, L. O. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (tafi) by thrombin Journal of Biological Chemistry  2011 286:502-510  DOI:10.1074/jbc.M110.147959  PMID:21041299  PMCID:PMC3013010
• Fernandes, N., Mosnier, L. O., Tonnu, L., Heeb, M. J. Zn(2+)-containing protein S inhibits extrinsic factor X-activating complex independently of tissue factor pathway inhibitor Journal of Thrombosis and Haemostasis  2010 8:1976-1985  DOI:10.1111/j.1538-7836.2010.03919.x  PMID:20492471  PMCID:PMC2955986
• Mosnier, L. O., Zampolli, A., Kerschen, E. J., Schuepbach, R. A., Banerjee, Y., Fernandez, J. A., Yang, X. V., Riewald, M., Weiler, H., Ruggeri, Z. M., Griffin, J. H. Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant Blood  2009 113:5970-5978  DOI:10.1182/blood-2008-10-183327  PMID:19244160  PMCID:PMC2700330
• Yang, X. V., Banerjee, Y., Fernandez, J. A., Deguchi, H., Xu, X., Mosnier, L. O., Urbanus, R. T., de Groot, P. G., White-Adams, T. C., McCarty, O. J. T., Griffin, J. H. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells Proceedings of the National Academy of Sciences of the United States of America  2009 106:274-279  DOI:10.1073/pnas.0807594106  PMID:19116273  PMCID:PMC2629184
• Mosnier, L. O., Yang, X. V., Griffin, J. H. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions Journal of Biological Chemistry  2007 282:33022-33033  DOI:10.1074/jbc.M705824200  PMID:17872949
• Kerschen, E. J., Fernandez, J. A., Cooley, B. C., Yang, X. V., Sood, R., Mosnier, L. O., Castellino, F. J., Mackman, N., Griffin, J. H., Weiler, H. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C Journal of Experimental Medicine  2007 204:2439-2448  DOI:10.1084/jem.20070404  PMID:17893198  PMCID:PMC2118455
• Griffin, J. H., Fernandez, J. A., Gale, A. J., Mosnier, L. O. Activated protein C Journal of Thrombosis and Haemostasis  2007 5:73-80  DOI:10.1111/j.1538-7836.2007.02491.x  PMID:17635713
• Mosnier, L. O., Zlokovic, B. V., Griffin, J. H. The cytoprotective protein C pathway Blood  2007 109:3161-3172  DOI:10.1182/blood-2006-09-003004  PMID:17110453
• Mosnier, L. O., Bouma, B. N. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase b that unites the pathways of coagulation and fibrinolysis Arteriosclerosis, Thrombosis, and Vascular Biology  2006 26:2445-2453  DOI:10.1161/01.ATV.0000244680.14653.9a  PMID:16960106
• Mosnier, L. O., Griffin, J. H. Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities Frontiers in Bioscience  2006 11:2381-2399  DOI:10.2741/1977  PMID:16720321
• Feistritzer, C., Schuepbach, R. A., Mosnier, L. O., Bush, L. A., Di Cera, E., Griffin, J. H., Riewald, M. Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells Journal of Biological Chemistry  2006 281:20077-20084  DOI:10.1074/jbc.M600506200  PMID:16709569
• Griffin, J. H., Fernandez, J. A., Mosnier, L. O., Liu, D., Cheng, T., Guo, H., Zlokovic, B. V. The promise of protein C Blood Cells Molecules and Diseases  2006 36:211-216  DOI:10.1016/j,bcmd.2005.12.023  PMID:16464623
• Bouma, B. N., Mosnier, L. O. Thrombin activatable fibrinolysis inhibitor (tafi) - how does thrombin regulate fibrinolysis? Annals of Medicine  2006 38:378-388  DOI:10.1080/07853890600852898  PMID:17008302
• Mosnier, L. O., Gale, A. J., Yegneswaran, S., Griffin, J. H. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity Blood  2004 104:1740-1744  DOI:10.1182/blood-2004-01-0110  PMID:15178575
• Mosnier, L. O., Griffin, J. H. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor Biochemical Journal  2003 373:65-70  DOI:10.1042/bj20030341  PMID:12683950
• Mosnier, L. O., Buijtenhuijs, P., Marx, P. F., Meijers, J. C. M., Bouma, B. N. Identification of thrombin activatable fibrinolysis inhibitor (tafi) in human platelets Blood  2003 101:4844-4846  DOI:10.1182/blood-2002-09-2944  PMID:12595308
• Reijerkerk, A., Mosnier, L. O., Kranenburg, O., Bouma, B. N., Carmeliet, P., Drixler, T., Meijers, J. C. M., Voest, E. E., Gebbink, Mfbg Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system Molecular Cancer Research  2003 1:561-568  PMID:12805403
• Bouma, B. N., Mosnier, L. O. Thrombin activatable fibrinolysis inhibitor (tafi) at the interface between coagulation and fibrinolysis Pathophysiology of Haemostasis and Thrombosis  2003 33:375-381  DOI:10.1159/000083832  PMID:15692247
• Lisman, T., Mosnier, L. O., Lambert, T., Mauser-Bunschoten, E. P., Meijers, J. C. M., Nieuwenhuis, H. K., de Groot, P. G. Inhibition of fibrinolysis by recombinant factor viia in plasma from patients with severe hemophilia a Blood  2002 99:175-179  DOI:10.1182/blood.V99.1.175  PMID:11756168
• Mosnier, L. O., Elisen, Mglm, Bouma, B. N., Meijers, J. C. M. Protein c inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of tafi activation Thrombosis and Haemostasis  2001 86:1057-1064  PMID:11686324
• Mosnier, L. O., Lisman, T., van den Berg, H. M., Nieuwenhuis, H. K., Meijers, J. C. M., Bouma, B. N. The defective down regulation of fibrinolysis in haemophilia a can be restored by increasing the tafi plasma concentration Thrombosis and Haemostasis  2001 86:1035-1039  PMID:11686321
• Mosnier, L. O., Meijers, J. C. M., Bouma, B. N. The role of protein s in the activation of thrombin activatable fibrinolysis inhibitor (tafi) and regulation of fibrinolysis Thrombosis and Haemostasis  2001 86:1040-1046  PMID:11686322
• Lisman, T., Leebeek, F. W. G., Mosnier, L. O., Bouma, B. N., Meijers, J. C. M., Janssen, H. L. A., Nieuwenhuis, H. K., De Groot, P. G. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis Gastroenterology  2001 121:131-139  DOI:10.1053/gast.2001.25481  PMID:11438502
• Bouma, B. N., Marx, P. F., Mosnier, L. O., Meijers, J. C. M. Thrombin-activatable fibrinolysis inhibitor (tafi, plasma procarboxypeptidase b, procarboxypeptidase r, procarboxypeptidase u) Thrombosis Research  2001 101:329-354  DOI:10.1016/s0049-3848(00)00411-4  PMID:11297751
• Rebel, H., Mosnier, L. O., Berg, R. J. W., Westerman-de Vries, A., van Steeg, H., van Kranen, H. J., de Gruijl, F. R. Early p53-positive foci as indicators of tumor risk in ultraviolet-exposed hairless mice: Kinetics of induction, effects of DNA repair deficiency, and p53 heterozygosity Cancer Research  2001 61:977-983  PMID:11221893
• Mosnier, L. O., Meijers, J. C. M., Bouma, B. N. Regulation of fibrinolysis in plasma by tafi and protein c is dependent on the concentration of thrombomodulin Thrombosis and Haemostasis  2001 85:5-11  PMID:11204587
• Meijers, J. C. M., Oudijk, E. J. D., Mosnier, L. O., Bos, R., Bouma, B. N., Nieuwenhuis, H. K., Fijnheer, R. Reduced activity of tafi (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia British Journal of Haematology  2000 108:518-523  DOI:10.1046/j.1365-2141.2000.01890.x  PMID:10759708
• Bouma, B. N., Mosnier, L. O., Meijers, J. C. M., Griffin, J. H. Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation Thrombosis and Haemostasis  1999 82:1703-1708  PMID:10613658
• Mosnier, L. O., von dem Borne, P. A. K., Meijers, J. C. M., Bouma, B. N. Plasma tafi levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation Thrombosis and Haemostasis  1998 80:829-835  PMID:9843179
• Minnema, M. C., Friederich, P. W., Levi, M., von dem Borne, P. A. K., Mosnier, L. O., Meijers, J. C. M., Biemond, B. J., Hack, C. E., Bouma, B. N., ten Cate, H. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor xi - in vivo evidence for a role of factor xi as an anti-fibrinolytic factor Journal of Clinical Investigation  1998 101:10-14  DOI:10.1172/jci781  PMID:9421460
• vondemBorne, P. A. K., Mosnier, L. O., Tans, G., Meijers, J. C. M., Bouma, B. N. Factor xi activation by meizothrombin: Stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine Thrombosis and Haemostasis  1997 78:834-839  PMID:9268180